Hyun Lee

List of Publications by Year in descending order

46 papers	1,904 citations	361296 20 h-index	276775 41 g-index
47 all docs	47 docs citations	47 times ranked	3215 citing authors

#	Article	IF	Citations
1	Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. Journal of Medicinal Chemistry, 2022, 65, 2940-2955.	2.9	102
2	Chemical constituents of Entandrophragma angolense and their anti-inflammatory activity. Phytochemistry, 2022, 201, 113276.	1.4	2
3	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. PLoS Pathogens, 2021, 17, e1009312.	2.1	16
4	Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. Cell and Bioscience, 2021, 11, 45.	2.1	47
5	Targeting SARSâ€CoVâ€2 viral proteases as a therapeutic strategy to treat COVIDâ€19. Journal of Medical Virology, 2021, 93, 2722-2734.	2.5	41
6	Limonoids and other triterpenoids from Entandrophragma angolense. FÃ¬toterapÃ¬Ã¢, 2021, 150, 104846.	1.1	7
7	Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. Antiviral Research, 2021, 190, 105075.	1.9	44
8	Histatinâ€1 is an endogenous ligand of the sigmaâ€2 receptor. FEBS Journal, 2021, 288, 6815-6827.	2.2	6
9	Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science, 2021, 373, 931-936.	6.0	173
10	Identification of Small Molecule Inhibitors against Staphylococcus aureus Dihydroorotase via HTS. International Journal of Molecular Sciences, 2021, 22, 9984.	1.8	6
11	Rufomycins or Ilamycins: Naming Clarifications and Definitive Structural Assignments. Journal of Natural Products, 2021, 84, 2644-2663.	1.5	10
12	MD simulations reveal alternate conformations of the oxyanion hole in the Zika virus NS2B/NS3 protease. Proteins: Structure, Function and Bioinformatics, 2020, 88, 345-354.	1.5	6
13	Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition. Journal of Biological Chemistry, 2020, 295, 15013-15028.	1.6	14
14	Antimycobacterial Rufomycin Analogues from Streptomyces atratus Strain MJM3502. Journal of Natural Products, 2020, 83, 657-667.	1.5	28
15	Structure of the N-terminal domain of ClpC1 in complex with the antituberculosis natural product ecumicin reveals unique binding interactions. Acta Crystallographica Section D: Structural Biology, 2020, 76, 458-471.	1.1	23
16	Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	68
17	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of vraTSR Expression in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
18	Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2349-2353.	1.0	4

#	Article	IF	Citations
19	High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads. ACS Infectious Diseases, 2019, 5, 829-840.	1.8	40
20	Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling. Bioorganic and Medicinal Chemistry, 2019, 27, 1981-1989.	1.4	23
21	Nonimmune cellâ€“derived ICOS ligand functions as a renoprotective Î±vÎ²3 integrinâ€“selective antagonist. Journal of Clinical Investigation, 2019, 129, 1713-1726.	3.9	19
22	Hit-to-Lead: Hit Validation and Assessment. Methods in Enzymology, 2018, 610, 265-309.	0.4	23
23	Structural characterization ofPorphyromonas gingivalisenoyl-ACP reductase II (FabK). Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 105-112.	0.4	11
24	Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2837-2841.	1.0	0
25	Airway Epithelial Cell-Derived Colony Stimulating Factor-1 Promotes Allergen Sensitization. Immunity, 2018, 49, 275-287.e5.	6.6	57
26	Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Research, 2017, 139, 49-58.	1.9	113
27	Insights into substrate promiscuity of human seryl-tRNA synthetase. Rna, 2017, 23, 1685-1699.	1.6	25
28	A tripartite complex of suPAR, APOL1 risk variants and Î±vÎ²3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017, 23, 945-953.	15.2	176
29	Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. , 2016, 57, 3313.		34
30	Over-expression, purification, and confirmation of Bacillus anthracis transcriptional regulator NprR. Protein Expression and Purification, 2016, 125, 83-89.	0.6	13
31	Ca-asp bound X-ray structure and inhibition of Bacillus anthracis dihydroorotase (DHOase). Bioorganic and Medicinal Chemistry, 2016, 24, 4536-4543.	1.4	18
32	Identification of B. anthracis N5-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. Bioorganic and Medicinal Chemistry, 2016, 24, 596-605.	1.4	7
33	MMP14 Cleavage of VEGFR1 in the Cornea Leads to a VEGF-Trap Antiangiogenic Effect. , 2015, 56, 5450.		24
34	Inhibitor Recognition Specificity of MERS-CoV Papain-like Protease May Differ from That of SARS-CoV. ACS Chemical Biology, 2015, 10, 1456-1465.	1.6	114
35	Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. European Journal of Medicinal Chemistry, 2015, 103, 252-268.	2.6	88
36	Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings. Bioorganic and Medicinal Chemistry, 2014, 22, 167-177.	1.4	48

#	Article	IF	Citations
37	A colorimetric assay optimization for high-throughput screening of dihydroorotase by detecting ureido groups. Analytical Biochemistry, 2013, 441, 87-94.	1.1	5
38	High-level expression, purification, and characterization of Staphylococcus aureus dihydroorotase (PyrC) as a cleavable His-SUMO fusion. Protein Expression and Purification, 2013, 88, 98-106.	0.6	16
39	Synergistic Inhibitor Binding to the Papainâ€Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications. ChemMedChem, 2013, 8, 1361-1372.	1.6	19
40	High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes. PLoS ONE, 2013, 8, e75144.	1.1	21
41	Identification of Non-Macrocyclic Small Molecule Inhibitors against the NS3/4A Serine Protease of Hepatitis C Virus through in Silico Screening. Journal of Chemical Information and Modeling, 2012, 52, 2245-2256.	2.5	12
42	Reducing agents affect inhibitory activities of compounds: Results from multiple drug targets. Analytical Biochemistry, 2012, 423, 46-53.	1.1	31
43	Severe Acute Respiratory Syndrome Coronavirus Papain-like Novel Protease Inhibitors: Design, Synthesis, Proteinâ^'Ligand X-ray Structure and Biological Evaluation. Journal of Medicinal Chemistry, 2010, 53, 4968-4979.	2.9	129
44	Diphosphothreonine-Specific Interaction between an SQ/TQ Cluster and an FHA Domain in the Rad53-Dun1 Kinase Cascade. Molecular Cell, 2008, 30, 767-778.	4.5	74
45	Structure and Function of the Phosphothreonine-Specific FHA Domain. Science Signaling, 2008, 1, re12.	1.6	126
46	Identification of potential binding sites for the FHA domain of human Chk2 by in vitro binding studies. Biochemical and Biophysical Research Communications, 2003, 311, 803-808.	1.0	10